Changes in Hong Kong stocks | Giant Biotech (02367) rose more than 6% in the intraday period, Giazi Biomedical and Aesthetic Matrix Expansion Agency Says Public Opinion Risks Are Gradually Clear

The Zhitong Finance App learned that Giant Biotech (02367) rose more than 6% in the intraday period. As of press release, it had risen 4.13% to HK$26.22, with a turnover of HK$160 million.

According to the news, Giants Biomedical and Aesthetic Matrix has recently expanded. In June, the 753 collagen needle under Juzi Biotech was officially launched. It is the first recombinant type I collagen facial injection in China, and has differentiated into the injection market dominated by type III collagen. In the same month, the company's self-developed cross-linked recombinant type III full-length sequence collagen filler was approved by NMPA, making it the world's first similar product to improve neck lines.

Huachuang Securities released a research report saying that the Juzi Biomedical and Aesthetic Matrix has gradually taken shape, and public opinion risks on cosmetics have gradually cleared up and are beginning to emerge. Although medicine and aesthetics are still in the early stages of market education today and next year, and their performance contribution is low, the potential can be expected. Considering the valuation of consumer sentiment suppression in Hong Kong stocks, comprehensive consideration was given to the cosmetics business in '26, or 15 x PE, or 29 billion yuan in market value; when combined, the potential medical and aesthetic market value increased by 6 billion yuan, for a total target market value of 35 billion yuan.